Scarica l'app Stockscreener
6.7543
1.42%
0.0943
Dopo l'orario di chiusura:
6.79
0.0357
+0.53%
Aclarion Inc Borsa (ACON) Ultime notizie
Aclarion (NASDAQ:ACON) Upgraded by Wall Street Zen to Hold Rating - Defense World
Aclarion stock price target cut to $20 at Ascendiant Capital - Investing.com Australia
Aclarion stock price target cut to $20 at Ascendiant Capital By Investing.com - Investing.com India
Aclarion, Inc. (NASDAQ:ACON) Sees Large Drop in Short Interest - Defense World
Aclarion (NASDAQ:ACON) Trading Down 1.2% – Here’s Why - Defense World
Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site - Ortho Spine News
USC Medical Center Joins Groundbreaking AI Trial to Revolutionize Chronic Back Pain Diagnosis - Stock Titan
Aclarion, Inc. SEC 10-Q Report - TradingView
Aclarion (ACON) Expands CLARITY Trial with Texas Back Institute - GuruFocus
Aclarion Announces Texas Back Institute as New CLARITY Trial Site - Ortho Spine News
Aclarion announces Texas Back Insitute as new CLARITY trial site - TipRanks
Aclarion Inc. Partners with Texas Back Institute for CLARITY Clinical Trial to Enhance Chronic Low Back Pain Treatment - Nasdaq
History Says Now Is the Time to Buy Nvidia Stock - The Globe and Mail
Aclarion Welcomes Advocate Health as CLARITY Trial Site - Ortho Spine News
Major Breakthrough: Advocate Health to Test AI-Powered Spine Pain Diagnostic in 300-Patient Trial - Stock Titan
Aclarion secures funding for pivotal CLARITY trial - MSN
Aclarion Announces Commercial Agreement with Spine Institute of Louisiana - Ortho Spine News
Aclarion (ACON) Partners with Louisiana Spine Institute to Expan - GuruFocus
Aclarion announces agreement with the Spine Institute of Louisiana - TipRanks
Aclarion Expands Nociscan Access with Commercial Agreement at Spine Institute of Louisiana - Nasdaq
Revolutionary Spine Pain Technology Nociscan Achieves 97% Success Rate, Expands to 17 Medical Centers - Stock Titan
Aclarion stock hits 52-week low at $7.25 amid steep annual decline By Investing.com - Investing.com South Africa
Aclarion stock hits 52-week low at $7.25 amid steep annual decline - Investing.com
Aclarion, Inc. (NASDAQ:ACON) Short Interest Update - Defense World
Aclarion Inc Files For Mixed Shelf Of Up To $150 MlnSEC Filing - marketscreener.com
Aclarion Releases Updated Investor Presentation at Showcase - TipRanks
Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025 - The Manila Times
Aclarion, Inc. to Present at Planet MicroCap Showcase: VEGAS 2025 on Chronic Low Back Pain Solutions - Nasdaq
Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet ... - Bluefield Daily Telegraph
Aclarion's Revolutionary AI Approach to Chronic Back Pain: New Investor Strategy Revealed at MicroCap Vegas - Stock Titan
3 Reasons to Buy Amazon Stock Like There's No Tomorrow - The Globe and Mail
Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis - Ortho Spine News
Aclarion's Nociscan Demonstrates Cost-Effectiveness and Improved Surgical Success Compared to Provocative Discography - Nasdaq
New Research: AI-Powered Spine Technology Cuts Patient Costs by $1,712, Boosts Surgery Success 10% - Stock Titan
NOCISCAN touted as lumbar pain diagnostic advance - MSN
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub - The Manila Times
Aclarion, Inc. SEC 10-K Report - TradingView
Aclarion stock hits 52-week low at $9.68 amid steep annual decline - Investing.com Canada
Aclarion stock hits 52-week low at $9.68 amid steep annual decline By Investing.com - Investing.com South Africa
Aclarion ‘s Nociscan now available in Santa Monica at MICSC - TipRanks
Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California - The Manila Times
Revolutionary AI-Powered Back Pain Diagnostic Tool Gains Ground in Los Angeles Healthcare Market - Stock Titan
EXCLUSIVE: March's 20 Most-Searched Tickers On Benzinga Pro — Where Do Tesla, Nvidia, Apple, Applovin Stock Rank?Apple (NASDAQ:AAPL), Aclarion (NASDAQ:ACON) - Benzinga
Aclarion, Inc. Delays Annual Report Filing - TipRanks
Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives - Ortho Spine News
Aclarion provides corporate update following Q1 strategic initiatives - TipRanks
2.22%
2.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):